You just read:

Janssen Presents Switch Data for New HIV-1 Treatment SYMTUZA™ (D/C/F/TAF) and Second Study Supporting its Use in a Rapid Initiation Scenario

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Jul 24, 2018, 06:04 ET